stockportfolio.pro
Stocks / GLUE vs STAA
GLUE vs STAA
Monte Rosa Therapeutics, Inc. and STAAR Surgical Company side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Monte Rosa Therapeutics, Inc. (GLUE) | STAAR Surgical Company (STAA) | |
|---|---|---|
| Market cap | $1.5B | $1.5B |
| Revenue (latest FY) | $123.67M | $239.44M |
| Net income (latest FY) | $-38.63M | $-80.45M |
| Revenue growth (5y CAGR) | — | 7.9% |
| Net margin | -31.2% | -33.6% |
| Return on equity | -16.6% | -23.4% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 6 |
| Positive free cash flow | No | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open GLUE — free Open STAA — freeFrequently asked questions
Which is bigger, GLUE or STAA?
STAAR Surgical Company is larger by market capitalization — $1.5B versus $1.5B.
Which grows faster, GLUE or STAA?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.